The EU Biotech Act: A Fact Sheet
A FACT SHEET | JUNE 2026
The EU Biotech Act is intended to help Europe develop new medicines and health technologies more quickly.
For people affected by lung cancer, the Act could influence how clinical trials are run, how new treatments are developed and how technologies such as artificial intelligence are used in diagnosis and care.
Our fact sheet explains what the proposed Act is, why it is relevant to lung cancer and the areas Lung Cancer Europe is following as the legislation develops.
Key Points
Our position
The Act aims to strengthen biotechnology and speed up the development of medicines and health technologies in Europe.
It could support faster access to clinical trials and new treatments.
It includes changes relevant to clinical research and emerging technologies.
Lung Cancer Europe is monitoring the Act to help ensure the needs and experiences of people affected by lung cancer are considered.
